sorry, we can't preview this file
Table_2_The Profile of Immunophenotype and Genotype Aberrations in Subsets of Pediatric T-Cell Acute Lymphoblastic Leukemia.DOC
T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous malignancy, which reflects distinctive stages of T-cell differentiation arrest. We have revisited a cohort of pediatric T-ALL, in order to test if immunophenotypes associated with molecular alterations would predict the patient's outcome. Genetic mutations, translocations and copy number alterations were identified through Sanger sequencing, RT-PCR, FISH and multiplex ligation-dependent probe amplification (MLPA). We defined 8 immunophenotypic T-ALL subtypes through multiparametric flow cytometry: early T-cell precursor (ETP, n = 27), immature (n = 38), early cortical (n = 15), cortical (n = 50), late cortical (n = 53), CD4/CD8 double negative mature (n = 31), double positive mature (n = 35) and simple positive mature (n = 31) T-ALL. Deletions (del) or amplifications (amp) in at least one gene were observed in 87% of cases. The most frequent gene alterations were CDKN2A/Bdel (71.4%), NOTCH1mut (47.6%) and FBXW7mut (17%). ETP-ALL had frequent FLT3mut (22.2%) and SUZ12del (16.7%) (p < 0.001), while CDKN2A/Bdel were rarely found in this subtype (p < 0.001). The early cortical T-ALL subtype had high frequencies of NOTCH1mut and IL7Rmut (71%, 28.6%, respectively), whereas, mature T-ALL with double positive CD4/CD8 had the highest frequencies of STIL-TAL1 (36.7%), LEF1del (27.3%) and CASP8AP2del (22.7%). The co-existence of two groups of T-ALL with NOTCH1mut/IL7Rmut, and with TLX3/SUZ12del/NF1del/IL7Rmut, were characterized with statistical significance (p < 0.05) but only STIL-TAL1 (pOS 47.5%) and NOTCH1WT/FBXW7WT (pOS 55.3%) are predictors of poor T-ALL outcomes. In conclusion, we have observed that 8 T-ALL subgroups are characterized by distinct molecular profiles. The mutations in NOTCH1/FBXW7 and STIL-TAL1 rearrangement had a prognostic impact, independent of immunophenotype.
History
References
- https://doi.org//10.3324/haematol.2008.004150
- https://doi.org//10.1111/bjh.12882
- https://doi.org//10.3324/haematol.13543
- https://doi.org//10.1038/sj.leu.2404957
- https://doi.org//10.1016/j.beha.2010.08.002
- https://doi.org//10.1055/s-0033-1337966
- https://doi.org//10.1016/s1470-2045(08)70314-0
- https://doi.org//10.1038/nature10725
- https://doi.org//10.3324/haematol.2013.090233
- https://doi.org//10.1111/j.1365-2141.2011.08955
- https://doi.org//10.1038/ng.3909
- https://doi.org//10.18632/oncotarget.11796
- https://doi.org//10.3389/fped.2016.00110
- https://doi.org//10.1200/jco.2013.48.6522
- https://doi.org//10.3389/fonc.2018.00488
- https://doi.org//10.1016/j.bcmd.2015.12.003
- https://doi.org//10.1080/10428190903040014
- https://doi.org//10.1186/1471-2407-12-9
- https://doi.org//10.1126/science.1102160
- https://doi.org//10.1038/leu.2010.203
- https://doi.org//10.1038/ng.924
- https://doi.org//10.1016/j.arcmed.2016.11.015
- https://doi.org//10.1101/gr.092759.109
- https://doi.org//10.1016/s1535-6108(02)00018-1
- https://doi.org//10.3389/fimmu.2017.00032
- https://doi.org//10.1182/blood-2002-09-2913
- https://doi.org//10.1038/leu.2011.324
- https://doi.org//10.3324/haematol.2015.130179
- https://doi.org//10.1007/s00277-015-2474-0
- https://doi.org//10.1002/pbc.27496
- https://doi.org//10.1182/blood-2005-12-4956
- https://doi.org//10.1038/leu.2010.205
- https://doi.org//10.1038/ng1425
- https://doi.org//10.1038/ng2025
- https://doi.org//10.1016/j.celrep.2016.01.064
- https://doi.org//10.1016/j.ccell.2018.01.006
- https://doi.org//10.1158/2159-8290.cd-18-1005
- https://doi.org//10.1038/ng.542
- https://doi.org//10.1084/jem.20122727
- https://doi.org//10.1182/blood-2012-08-451278
- https://doi.org//10.1007/82_2012_231
- https://doi.org//10.1016/j.immuni.2012.08.009
- https://doi.org//10.1182/blood-2011-03-338707